|
WO2021048799A1
|
|
Method for identifying responders to smarca2/4 degraders
|
|
WO2020202001A1
|
|
Substituted 5-cyclopropyl-1h-pyrazol-3-yl-amine derivatives as selective cdk12/13 inhibitors
|
|
US2020147054A1
|
|
Combination of Small Molecule CD-47 Inhibitors with Other Anti-Cancer Agents
|
|
EP3784665A1
|
|
Pyridazine derivatives as smarca2/4 degraders
|
|
WO2019193509A1
|
|
Substituted pyrazole derivatives as selective cdk12/13 inhibitors
|
|
CN112105609A
|
|
Substituted imidazolidin-2-one derivatives as PRMT5 inhibitors
|
|
US2021002299A1
|
|
Imidazolidin-2-one compounds as prmt5 modulators
|
|
BR112020018555A2
|
|
METHOD OF MODULATING THE TIGIT AND PD-1 SIGNALING ROUTES USING 1,2,4-OXADIAZOL COMPOUNDS
|
|
WO2019142126A1
|
|
Substituted alkynylene compounds as anticancer agents
|
|
CA3087841A1
|
|
1,2,4-oxadiazole compounds as inhibitors of cd47 signalling pathways
|
|
AU2018360389A1
|
|
Conjoint therapies for immunomodulation
|
|
CN111372584A
|
|
Dual inhibitors of the TIM-3 and PD-1 pathways
|
|
CN111194308A
|
|
Crystalline forms of 3-substituted 1,2, 4-oxadiazoles
|
|
GB201808580D0
|
|
Heterocyclic compounds
|
|
GB201807557D0
|
|
Chemical compounds
|
|
CN110662539A
|
|
Method of using tri-substituted benzotriazole derivatives as dihydroorotate oxygenase inhibitors
|
|
AU2018242623A1
|
|
Compounds and compositions for treating hematological disorders
|
|
US2018369206A1
|
|
Methods of Use for Trisubstituted Benzotriazole Derivatives as Dihydroorotate Oxygenase Inhibitors
|
|
WO2018109650A1
|
|
Spiro[cyclopentane-1,3'-indolin]-2'-one derivatives as bromodomain inhibitors
|
|
MX2019004561A
|
|
Dual inhibitors of vista and pd-1 pathways.
|
